Reata Pharmaceuticals surged over 51% while Biogen slid slightly in morning trading.
Biogen Inc. said Friday it has agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion in cash in a deal that will help it expand its portfolio of treatments for rare diseases.
Reata (RETA) "has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases," Biogen said in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments